Insulin resistance and risk of vascular events, interventions and mortality in type 1 diabetes

in European Journal of Endocrinology
View More View Less
  • 1 Department of Vascular Medicine, University Medical Center Utrecht, Utrecht, the Netherlands
  • | 2 Department of Internal Medicine, University Medical Center Utrecht, Utrecht, the Netherlands

Correspondence should be addressed to J Westerink Email J.Westerink-3@umcutrecht.nl
Restricted access

Objective

To identify determinants associated with insulin resistance and to assess the association between insulin resistance and cardiovascular events, vascular interventions and mortality in people with type 1 diabetes at high risk of cardiovascular disease.

Design

Prospective cohort study.

Methods

One hundred and ninety-five people with type 1 diabetes from the Secondary Manifestations of ARTerial disease (SMART) cohort were included. Insulin resistance was quantified by the estimated glucose disposal rate (eGDR) with higher eGDR levels indicating higher insulin sensitivity (i.e. lower eGDR levels indicating higher insulin resistance). Linear regression models were used to evaluate determinants associated with eGDR. The effect of eGDR on cardiovascular events, cardiovascular events or vascular interventions (combined endpoint) and on all-cause mortality was analysed using Cox proportional hazards models adjusted for confounders.

Results

In 195 individuals (median follow-up 12.9 years, IQR 6.7–17.0), a total of 25 cardiovascular events, 26 vascular interventions and 27 deaths were observed. High eGDR as a marker for preserved insulin sensitivity was independently associated with a lower risk of cardiovascular events (HR: 0.75; 95% CI: 0.61–0.91), a lower risk of cardiovascular events and vascular interventions (HR: 0.74; 95% CI: 0.63–0.87) and a lower risk of all-cause mortality (HR: 0.81; 95% CI: 0.67–0.98).

Conclusions

Insulin resistance as measured by eGDR is an additional risk factor for cardiovascular disease in individuals with type 1 diabetes. Modification of insulin resistance by lifestyle interventions or pharmacological treatment could be a viable therapeutic target to lower the risk of cardiovascular disease.

 

     European Society of Endocrinology

Sept 2018 onwards Past Year Past 30 Days
Abstract Views 339 339 339
Full Text Views 20 20 20
PDF Downloads 29 29 29
  • 1

    De Ferranti SD, De Boer IH, Fonseca V, Fox CS, Golden SH, Lavie CJ, Magge SN, Marx N, McGuire DK & Orchard TJ et al.Type 1 diabetes mellitus and cardiovascular disease: a scientific statement from the American Heart Association and American Diabetes Association. Circulation 2014 130 11101130. (https://doi.org/10.1161/CIR.0000000000000034)

    • Search Google Scholar
    • Export Citation
  • 2

    Petrie D, Lung TWC, Rawshani A, Palmer AJ, Svensson AM, Eliasson B, Clarke P. Recent trends in life expectancy for people with type 1 diabetes in Sweden. Diabetologia 2016 59 11671176. (https://doi.org/10.1007/s00125-016-3914-7)

    • Search Google Scholar
    • Export Citation
  • 3

    Rawshani A, Rawshani A, Franzén S, Eliasson B, Svensson AM, Miftaraj M, McGuire DK, Sattar N, Rosengren A, Gudbjörnsdottir S. Mortality and cardiovascular disease in type 1 and type 2 diabetes. New England Journal of Medicine 2017 376 14071418. (https://doi.org/10.1056/NEJMoa1608664)

    • Search Google Scholar
    • Export Citation
  • 4

    Livingstone SJ, Levin D, Looker HC, Lindsay RS, Wild SH, Joss N, Leese G, Leslie P, McCrimmon RJ & Metcalfe W et al.Estimated life expectancy in a Scottish cohort with type 1 diabetes, 2008–2010. JAMA 2015 313 3744. (https://doi.org/10.1001/jama.2014.16425)

    • Search Google Scholar
    • Export Citation
  • 5

    Tran-Duy A, Knight J, Palmer AJ, Petrie D, Lung TWC, Herman WH, Eliasson B, Svensson AM, Clarke PM. A patient-level model to estimate lifetime health outcomes of patients with type 1 diabetes. Diabetes Care 2020 43 17411749. (https://doi.org/10.2337/dc19-2249)

    • Search Google Scholar
    • Export Citation
  • 6

    The National Institute for Health and Care Excellence. Type 1 diabetes in adults: diagnosis and management (Internet). 2016 (cited 2020 Oct 14). (available at: https://www.nice.org.uk/guidance/ng17)

    • Search Google Scholar
    • Export Citation
  • 7

    American Diabetes Association. Standards of medical care in diabetes – 2018. Diabetes Care 2018 37 (Supplement1) 1437. (https://doi.org/10.7326/M18-0222)

    • Search Google Scholar
    • Export Citation
  • 8

    Do children with type 2 diabetes in Canada have access to safe and effective treatment options? Canadian Journal of Diabetes 2018 42 (Supplement) S1S326. (https://doi.org/10.1016/j.jcjd.2017.12.004)

    • Search Google Scholar
    • Export Citation
  • 9

    Rawshani A, Rawshani A, Franzén S, Eliasson B, Svensson AM, Miftaraj M, McGuire DK, Sattar N, Rosengren A, Gudbjörnsdottir S. Range of risk factor levels: control, mortality, and cardiovascular outcomes in type 1 diabetes mellitus. Circulation 2017 135 15221531. (https://doi.org/10.1161/CIRCULATIONAHA.116.025961)

    • Search Google Scholar
    • Export Citation
  • 10

    Corbin KD, Driscoll KA, Pratley RE, Smith SR, Maahs DM, Mayer-Davis EJ & Advancing Care for Type 1 Diabetes and Obesity Network (ACT1ON). Obesity in type 1 diabetes: pathophysiology, clinical impact, and mechanisms. Endocrine Reviews 2018 39 629663. (https://doi.org/10.1210/er.2017-00191)

    • Search Google Scholar
    • Export Citation
  • 11

    Cleland SJ, Fisher BM, Colhoun HM, Sattar N, Petrie JR. Insulin resistance in type 1 diabetes: what is ‘double diabetes’ and what are the risks? Diabetologia 2013 56 14621470. (https://doi.org/10.1007/s00125-013-2904-2)

    • Search Google Scholar
    • Export Citation
  • 12

    Donga E, Dekkers OM, Corssmit EPM, Romijn JA. Insulin resistance in patients with type 1 diabetes assessed by glucose clamp studies: systematic review and meta-analysis. European Journal of Endocrinology 2015 173 101109. (https://doi.org/10.1530/EJE-14-0911)

    • Search Google Scholar
    • Export Citation
  • 13

    Vergès B Cardiovascular disease in type 1 diabetes: a review of epidemiological data and underlying mechanisms. Diabetes and Metabolism 2020 46 442449. (https://doi.org/10.1016/j.diabet.2020.09.001)

    • Search Google Scholar
    • Export Citation
  • 14

    Kilpatrick ES, Rigby AS, Atkin SL. Insulin resistance, the metabolic syndrome, and complication risk in type 1 diabetes: ‘Double diabetes’ in the diabetes control and complications trial. Diabetes Care 2007 30 707712. (https://doi.org/10.2337/dc06-1982)

    • Search Google Scholar
    • Export Citation
  • 15

    DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. American Journal of Physiology: Endocrinology Metabolism and Gastrointestinal Physiology 1979 237 E214E223. (https://doi.org/10.1152/ajpendo.1979.237.3.E214)

    • Search Google Scholar
    • Export Citation
  • 16

    Williams KV, Erbey JR, Becker D, Arslanian S, Orchard TJ. Can clinical factors estimate insulin resistance in type 1 diabetes? Diabetes 2000 49 626632. (https://doi.org/10.2337/diabetes.49.4.626)

    • Search Google Scholar
    • Export Citation
  • 17

    Garofolo M, Gualdani E, Scarale MG, Bianchi C, Aragona M, Campi F, Lucchesi D, Daniele G, Miccoli R & Francesconi P et al.Insulin resistance and risk of major vascular events and all-cause mortality in Type 1 diabetes: a 10-year follow-up study. Diabetes Care 2020 43 e139e141. (https://doi.org/10.2337/dc20-0433)

    • Search Google Scholar
    • Export Citation
  • 18

    Šimonienė D, Platūkiene A, Prakapienė E, Radzevičienė L, Veličkiene D. Insulin resistance in type 1 diabetes mellitus and its association with patient’s micro- and macrovascular complications, sex hormones, and other clinical data. Diabetes Therapy 2020 11 161174. (https://doi.org/10.1007/s13300-019-00729-5)

    • Search Google Scholar
    • Export Citation
  • 19

    Nyström T, Holzmann MJ, Eliasson B, Svensson AM, Sartipy U. Estimated glucose disposal rate predicts mortality in adults with type 1 diabetes. Diabetes, Obesity and Metabolism 2018 20 556563. (https://doi.org/10.1111/dom.13110)

    • Search Google Scholar
    • Export Citation
  • 20

    Pop A, Clenciu D, Anghel M, Radu S, Socea B, Mota E, Mota M, Panduru NM & RomDiane Study Group. Insulin resistance is associated with all chronic complications in type 1 diabetes. Journal of Diabetes 2016 8 220228. (https://doi.org/10.1111/1753-0407.12283)

    • Search Google Scholar
    • Export Citation
  • 21

    Orchard TJ, Olson JC, Erbey JR, Williams K, Forrest KYZ, Kinder LS, Ellis D, Becker DJ. Insulin resistance-related factors, but not glycemia, predict coronary artery disease in type 1 diabetes: 10-year follow-up data from the Pittsburgh epidemiology of diabetes complications study. Diabetes Care 2003 26 13741379. (https://doi.org/10.2337/diacare.26.5.1374)

    • Search Google Scholar
    • Export Citation
  • 22

    Simons PCG, Algra A, Van De Laak MF, Grobbee DE, Van Der Graaf Y. Second manifestations of arterial disease (SMART) study: rationale and design. European Journal of Epidemiology 1999 15 773781. (https://doi.org/10.1023/a:1007621514757)

    • Search Google Scholar
    • Export Citation
  • 23

    Coelho S What is the role of HbA1c in diabetic hemodialysis patients? Seminars in Dialysis 2016 29 1923. (https://doi.org/10.1111/sdi.12408)

    • Search Google Scholar
    • Export Citation
  • 24

    Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ & Smith SC et al.Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005 112 27352752. (https://doi.org/10.1161/CIRCULATIONAHA.105.169404)

    • Search Google Scholar
    • Export Citation
  • 25

    Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, Feldman HI, Kusek JW, Eggers P, Lente Van F & Greene T et al.A new equation to estimate glomerular filtration rate. Annals of Internal Medicine 2009 150 604612. (https://doi.org/10.7326/0003-4819-150-9-200905050-00006)

    • Search Google Scholar
    • Export Citation
  • 26

    Tremblay AJ, Morrissette H, Gagné JM, Bergeron J, Gagné C, Couture P. Validation of the Friedewald formula for the determination of low-density lipoprotein cholesterol compared with β-quantification in a large population. Clinical Biochemistry 2004 37 785790. (https://doi.org/10.1016/j.clinbiochem.2004.03.008)

    • Search Google Scholar
    • Export Citation
  • 27

    Krochik AG, Botto M, Bravo M, Hepner M, Frontroth JP, Miranda M, Mazza C. Association between insulin resistance and risk of complications in children and adolescents with type 1 diabetes. Diabetes and Metabolic Syndrome 2015 9 1418. (https://doi.org/10.1016/j.dsx.2014.09.013)

    • Search Google Scholar
    • Export Citation
  • 28

    Epstein EJ, Osman JL, Cohen HW, Rajpathak SN, Lewis O, Crandall JP. Use of the estimated glucose disposal rate as a measure of insulin resistance in an urban multiethnic population with type 1 diabetes. Diabetes Care 2013 36 22802285. (https://doi.org/10.2337/dc12-1693)

    • Search Google Scholar
    • Export Citation
  • 29

    Miller RG, Costacou T, Orchard TJ. Risk factor modeling for cardiovascular disease in type 1 diabetes in the Pittsburgh epidemiology of diabetes complications (EDC) study: a comparison with the diabetes control and complications trial/epidemiology of diabetes interventions and complications study (DCCT/EDIC). Diabetes 2019 68 409419. (https://doi.org/10.2337/db18-0515)

    • Search Google Scholar
    • Export Citation
  • 30

    Januszewski AS, Sachithanandan N, Ward G, Karschimkus CS, O’Neal DN, Jenkins AJ. Estimated insulin sensitivity in Type 1 diabetes adults using clinical and research biomarkers. Diabetes Research and Clinical Practice 2020 167 108359. (https://doi.org/10.1016/j.diabres.2020.108359)

    • Search Google Scholar
    • Export Citation
  • 31

    Kietsiriroje N, Pearson S, Campbell M, Ariëns RAS, Ajjan RA. Double diabetes: a distinct high-risk group? Diabetes, Obesity and Metabolism 2019 21 26092618. (https://doi.org/10.1111/dom.13848)

    • Search Google Scholar
    • Export Citation
  • 32

    Spoto B, Pisano A, Zoccali C. Insulin resistance in chronic kidney disease: a systematic review. American Journal of Physiology: Renal Physiology 2016 311 F1087F1108. (https://doi.org/10.1152/ajprenal.00340.2016)

    • Search Google Scholar
    • Export Citation
  • 33

    Johansen NJ, Dejgaard TF, Lund A, Schlüntz C, Frandsen CS, Forman JL, Wewer Albrechtsen NJ, Holst JJ, Pedersen-Bjergaard U & Madsbad S et al.Efficacy and safety of meal-time administration of short-acting exenatide for glycaemic control in type 1 diabetes (MAG1C): a randomised, double-blind, placebo-controlled trial. Lancet: Diabetes and Endocrinology 2020 8 313324. (https://doi.org/10.1016/S2213-8587(2030030-9)

    • Search Google Scholar
    • Export Citation
  • 34

    Mathieu C, Zinman B, Hemmingsson JU, Woo V, Colman P, Christiansen E, Linder M, Bode B & ADJUNCT ONE Investigators. Efficacy and safety of liraglutide added to insulin treatment in type 1 diabetes: the adjunct one treat-to-target randomized trial. Diabetes Care 2016 39 17021710. (https://doi.org/10.2337/dc16-0691)

    • Search Google Scholar
    • Export Citation
  • 35

    Liu YS, Chen CN, Chen ZG, Peng Y, Lin XP, Xu LL. Vascular and metabolic effects of metformin added to insulin therapy in patients with type 1 diabetes: a systematic review and meta-analysis. Diabetes/Metabolism Research and Reviews 2020 36 e3334. (https://doi.org/10.1002/dmrr.3334)

    • Search Google Scholar
    • Export Citation
  • 36

    Danne T, Cariou B, Banks P, Brandle M, Brath H, Franek E, Kushner JA, Lapuerta P, McGuire DK & Peters AL et al.HbA1c and hypoglycemia reductions at 24 and 52 weeks with sotagliflozin in combination with insulin in adults with type 1 diabetes: the European in Tandem2 study. Diabetes Care 2018 41 19811990. (https://doi.org/10.2337/dc18-0342)

    • Search Google Scholar
    • Export Citation
  • 37

    Mathieu C, Dandona P, Phillip M, Oron T, Lind M, Hansen L, Thorén F, Xu J, Langkilde AM & DEPICT-1 and DEPICT-2 Investigators. Glucose variables in type 1 diabetes studies with dapagliflozin: pooled analysis of continuous glucose monitoring data from DEPICT-1 and -2. Diabetes Care 2019 42 10811087. (https://doi.org/10.2337/dc18-1983)

    • Search Google Scholar
    • Export Citation
  • 38

    Rosenstock J, Marquard J, Laffel LM, Neubacher D, Kaspers S, Cherney DZ, Zinman B, Skyler JS, George J & Soleymanlou N et al.Empagliflozin as adjunctive to insulin therapyin type 1 diabetes: the EASE trials. Diabetes Care 2018 41 25602569. (https://doi.org/10.2337/dc18-1749)

    • Search Google Scholar
    • Export Citation
  • 39

    Markham A, Keam SJ. Sotagliflozin: first global approval. Drugs 2019 79 10231029. (https://doi.org/10.1007/s40265-019-01146-5)

  • 40

    Peters AL, McGuire DK, Danne T, Kushner JA, Rodbard HW, Dhatariya K, Sawhney S, Banks P, Jiang W & Davies MJ et al.Diabetic ketoacidosis and related events with sotagliflozin added to insulin in adults with type 1 diabetes: a pooled analysis of the intandem 1 and 2 studies. Diabetes Care 2020 43 27132720. (https://doi.org/10.2337/dc20-0924)

    • Search Google Scholar
    • Export Citation